Y-mabs Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy YMAB

*Your capital is at risk

$8.61

+0 (+0%)

At Close: Dec 15, 2025

Y-mAbs Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -100.00. In total, the insiders bought 0 and sold 11.5M YMAB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-100.00
● Buy	0 shares
● Sell	11.5M shares
0% Buy Activity Moderate Negative Correlation
Sell Signal High Confidence Sep 16, 2025 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -100. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (0% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Sep 16, 2025 Sell	Common Stock D-Return	Wedell-wedellsborg Johan	Director	25 080 Value: $0
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Wedell-wedellsborg Johan	Director	36 000 Value: $157.7K
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Wedell-wedellsborg Johan	Director	32 000 Value: $357.1K
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Wedell-wedellsborg Johan	Director	16 000 Value: $343.2K
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Wedell-wedellsborg Johan	Director	11 000 Value: $535.4K
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Wedell-wedellsborg Johan	Director	11 000 Value: $412.8K
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Wedell-wedellsborg Johan	Director	16 000 Value: $266.2K
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Wedell-wedellsborg Johan	Director	13 950 Value: $113.4K
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Wedell-wedellsborg Johan	Director	14 545 Value: $174.7K
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Wedell-wedellsborg Johan	Director	33 450 Value: $150.9K
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Larocca John SVP, General Counsel & Secry	Officer	42 900 Value: $264.3K
Sep 16, 2025 Sell	Common Stock D-Return	Larocca John SVP, General Counsel & Secry	Officer	21 500 Value: $184.9K
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Larocca John SVP, General Counsel & Secry	Officer	142 600 Value: $1.40M
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Healy James Director	Director	14 222 Value: $158.7K
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Healy James Director	Director	8 000 Value: $171.6K
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Healy James Director	Director	11 000 Value: $535.4K
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Healy James Director	Director	11 000 Value: $412.8K
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Healy James Director	Director	16 000 Value: $266.2K
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Healy James Director	Director	13 950 Value: $113.4K
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Healy James Director	Director	33 450 Value: $150.9K
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Healy James Director	Director	14 545 Value: $174.7K
Sep 16, 2025 Sell	Common Stock U-Tender	Healy James Director	Director	2 194 278 Value: $18.9M
Sep 16, 2025 Sell	Common Stock D-Return	Healy James Director	Director	25 080 Value: $0
Sep 16, 2025 Sell	Employee Stock Option (right to buy) D-Return	Rossi Michael J President & CEO	CEO / President	210 700 Value: $1.30M
Sep 16, 2025 Sell	Common Stock U-Tender	Wilms Joris SVP & Chief Operating Officer	C-Suite Officer	12 799 Value: $110.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT Y-MABS THERAPEUTICS INC.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developin...

Read Full Profile Here